PharmaEngine Inc. announced the appointment of Alain Herrera, MD, as Senior Advisor. He will advise on its clinical strategy and operations, as well as corporate strategy, licensing and alliance management. The company believes that the addition of Dr. Herrera will open a new page of clinical and corporate development for the company.

Prior to founding his own consultancy firm, Alain Oncologie Consulting, he headed the global oncology business at sanofi-aventis for ten years, as Vice President, Global Oncology Business Strategy and Development, and contributed to the worldwide registration of Oxaliplatin Eloxatin(R) and Rasburicase Fasturtec(R)/Elitek(R), as well as the gastric and head & neck indications for Docetaxel Taxotere(R) . Other positions include Chairman of Chiron Therapeutics Europe, Managing Director at Pierre Fabre Oncology Laboratories. While at Roger Bellon (Rhône Poulenc), he was involved in evaluating the licensing of irinotecan from Yakult Co.

Ltd. (Japan) and was responsible for its early clinical development.